SynthesisProceedings (Baylor University. Medical Center)2026
Efficacy and safety of low-dose versus standard-dose direct oral anticoagulants for secondary prevention of cancer-associated thrombosis: a systematic review and meta-analysis.
Synthesis in Proceedings (Baylor University. Medical Center), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deep vein thrombosis prevention and bleeding risks in the cancer patient: are we entering a new era of DVT prophylaxis?Proceedings (Baylor University. Medical Center) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer and is associated with a high risk of both recurrent venous thromboembolism (VTE) and bleeding. Although extended anticoagulation reduces the risk of recurrent VTE by more than 80%, full-dose therapy may increase bleeding complications, potentially offsetting its benefit in this population. Reduced-dose direct oral anticoagulants (DOACs) have therefore been proposed as a safer long-term treatment option.
methodsWe conducted a systematic review and meta-analysis of randomized controlled trials comparing reduced-dose DOACs with standard-dose regimens for extended VTE treatment in cancer patients. Outcomes included recurrent VTE, major bleeding, clinically relevant nonmajor bleeding, all-cause mortality, and composite bleeding, with pooled odds ratios calculated using random-effects models.
resultsFive randomized trials involving 2709 patients were included. Recurrent VTE rates were comparable between reduced-dose and standard-dose DOACs. Reduced-dose therapy was associated with a significant reduction in clinically relevant nonmajor bleeding and composite bleeding. While major bleeding occurred less, the difference was not statistically significant.
conclusionsOverall, reduced-dose DOACs demonstrated similar efficacy in preventing recurrent VTE while offering an improved bleeding profile, supporting their potential role in long-term management of cancer-associated thrombosis, though larger prospective studies are needed to define optimal dosing strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.